AKIGAI

Executive Summary

AKIGAI is a Norwegian biotech startup founded in 2020, focused on developing disruptive treatments for neuropathic pain. The company holds a global use patent for repurposing existing drugs that have a long history of safe use in millions of patients over more than 20 years. By leveraging known safety profiles, AKIGAI aims to accelerate development and reduce the typical risks associated with novel drug candidates. Their approach combines AI and machine learning to optimize drug selection and repurposing, positioning them at the intersection of digital health and pharmaceutical innovation. As a private, early-stage company, AKIGAI has yet to disclose funding, valuation, or clinical milestones. However, the repurposing strategy could enable a faster path to market compared to traditional drug development. The company is based in Oslo, Norway, and operates in the competitive neuropathic pain space, which represents a significant unmet medical need. Key upcoming catalysts include the initiation of clinical trials, further patent issuances, and potential licensing or partnership agreements with larger pharmaceutical firms. While still preclinical or early clinical, AKIGAI's novel approach and experienced team may offer a compelling investment thesis for those focused on de-risked drug development.

Upcoming Catalysts (preview)

• Q4 2026Initiation of Phase 1 or Phase 2 Clinical Trial60% success
• Q2 2026Grant or Expansion of Global Use Patent70% success
• Q1 2027Strategic Partnership or Licensing Agreement40% success